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The association between vitamin D deficiency and multiple sclerosis (MS) is well described.
We set out to use remote sampling to ascertain vitamin D status and vitamin D supplemen-
tation in a cross-sectional study of people with MS across the UK.
Methods
People with MS and matched controls were recruited from across the UK. 1768 people with
MS enrolled in the study; remote sampling kits were distributed to a subgroup. Dried blood
spots (DBS) were used to assess serum 25(OH)D in people with MS and controls.
Results
1768 MS participants completed the questionnaire; 388 MS participants and 309 controls
provided biological samples. Serum 25(OH)D was higher in MS than controls (median
71nmol/L vs 49nmol/L). A higher proportion of MS participants than controls supplemented
(72% vs 26%, p<0.001); people with MS supplemented at higher vD doses than controls
(median 1600 vs 600 IU/day, p<0.001). People with MS who did not supplement had lower
serum 25(OH)D levels than non-supplementing controls (median 38 nmol/L vs 44 nmol/L).
Participants engaged well with remote sampling.
Conclusions
The UK MS population have higher serum 25(OH)D than controls, mainly as a result of vita-
min D supplementation. Remote sampling is a feasible way of carrying out large studies.
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Introduction
MS susceptibility is a complex trait influenced by genetic and environmental factors. Estab-
lished environmental risk factors include EBV seropositivity, smoking, and childhood obesity
[1–3]. Low serum 25-hydroxyvitamin D (25(OH)D) levels in adulthood, or even soon after
birth, are associated with greater risk of developing multiple sclerosis (MS) [4–6]. Vitamin D is
primarily derived from the UV light-dependent conversion of 7-dehydrocholesterol to chole-
calciferol in skin. Serum 25(OH)D is formed by the hepatic 25-hydroxylation of cholecalcif-
erol, which is further hydroxylated in the kidney to generate the biologically active compound
(1,25 hydroxyvitamin D). 25(OH)D is most commonly used as a measure of vitamin D status
due to its long half-life, relative stability and direct biological relationship to 1,25 hydroxyvita-
min D [7].
Vitamin D is an attractive target for potential intervention in MS as it represents an easily
modifiable factor. However, data is conflicting regarding the role of vitamin D in driving
inflammation and/or progression in people with established MS. Clinical trials of vitamin D
supplementation in MS have failed to provide robust evidence of benefit [8–11]. Several recent
meta-analyses looking at clinical trials of vitamin D for the treatment of MS have demon-
strated at best modest reductions in annualised relapse rates (ARR) and/or brain lesion activity
but no impact on disability [12–14].
There are thought to be multiple factors influencing vitamin D status in MS populations
[15]. Current population guidelines recommend an intake of at least 400IU/day vitamin D
for all [16]. There is a lack of consensus and evidence on whether people with MS should be
advised to supplement with vitamin D over and above the advice given to the general popu-
lation. Single centre studies examining vitamin D supplementation behaviours are subject
to bias due to practices of individual neurologists; collecting supplementing information
without the wider lifestyle context or serum vitamin D levels significantly limits
interpretation.
Remote sampling using dried blood spots provides a means of testing biomarkers across an
entire population without the need for in-person visits, which is of rapidly increasing relevance
in the current COVID-19 pandemic. We set out to examine the feasibility of a large-scale
research project performed entirely remotely, including remote sampling using dried blood
spots. We used remotely deployed questionnaires backed up with biological sampling to exam-
ine the behaviours and lifestyle factors that influence vitamin D and assess their contribution
to the serum vitamin D status across the UK MS population.
Methods
Study recruitment
The primary method of recruitment was via the UK MS Register [17]. 14,991 individuals with
MS were invited to participate; 1722 people with MS provided informed consent and com-
pleted a baseline questionnaire over 6 weeks using the online platform; an additional 25
participants (postal participants) directly contacted the study site (Fig 1). Individuals were
additionally recruited via regional MS networks. Questionnaires with sampling kits were dis-
tributed to three MS clinics across the UK—Edinburgh, Lanarkshire and London. 68 sampling
kits were handed out to potential participants.
Each MS participant who was given a sampling pack was asked to recruit an unrelated
friend as a matched control. They were asked to select someone of the same gender, within 5
years of age and living within a 50-mile radius (but not in the same house) as themselves.
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Fig 1. Flow chart of the study recruitment and resulting study population. 388 MS participants and 309 matched controls
returned sampling kits. In some cases, data or biological material was not available for all data points, resulting in 388 MS with data
and 371 MS with DBS and 305 controls with data and 309 controls with DBS.
https://doi.org/10.1371/journal.pone.0241459.g001
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Ethical permissions
The UK MS Register has ethical approval via South West Bristol REC (16/SW/0194). This
study had additional ethical permissions via London Stanmore REC (18/LO/1455).
Stratified random sampling
Stratified random sampling was used to select 575 UK MS register participants to receive
kits. Participants were grouped (stratified) based on geographical location (100km x 100km
square), MS type (RRMS, SPMS, PPMS) and disability (low disability classified as EDSS
<6, high disability EDSS�6). Random sampling within groups was then performed. This
approach attempted to ensure that we had a balance across geographical areas, MS disease
types, and EDSS in order that we could make meaningful comparisons between pre-speci-
fied subgroups or potential influences of interest. If we had sought to represent the initial
respondents we would not have had enough individuals in some cells in order to be able to
perform such analyses.
Questionnaire data
A host of demographic and MS-specific data were collected including geographical location,
gender, age, BMI, smoking status, MS type, EDSS, MSIS and date of diagnosis. Where available,
Expanded Disability Status Scores (EDSS) derived from a web-based application were used as a
proxy for disability levels [18], and estimates of disease physical and psychological impact via
the Multiple Sclerosis Impact Scale (MSIS-29). Data on current vitamin D supplementation
was collected including supplement use, frequency, and dose at the time of questionnaire com-
pletion. Participants completing the online form were invited to upload an image of their sup-
plement to validate supplement dose. Information of diet type and consumption of oily fish,
and assessment of time spent on outdoor activities and UV sun protection averaged over the
past 3 months was also collected. To ensure complete capture of sun protection factor contain-
ing products in addition to sunblock (moisturiser, foundation, mineral powder etc.), partici-
pants were asked about both ‘cosmetic sunblock’ and ‘sunblock’ usage.
Sampling kits
Each sampling pack contained two sampling kits, one for the MS participant and one for their
matched control. Each sampling kit contained a fully equipped dried blood spot (DBS) sam-
pling system to collect a blood sample for vitamin D analysis, and a buccal swab for genetic
material. A questionnaire was included for controls, and for those MS participants where data
was not entered via the online system. Sampling packs were sent out February-July 2019. Sam-
ples were received back at the study site February-September 2019.
25(OH)Vitamin D analysis
Serum vitamin D concentrations were measured from DBS [19]. Upon receipt samples were
stored at -80˚C and underwent analysis in four batches. Liquid chromatography tandem mass
spectrometry was used to determine total 25(OH)D [20, 21]. Two DBS were analysed per par-
ticipant; results were excluded if duplicate analysis differed by�15%, if only one viable DBS
was available, or if DBS were deemed to be of poor quality, i.e, spots too small, not fully soaked
through or multiple overlapping spots.
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Vitamin D levels and MS in UK Biobank
We then set out to verify our findings using an independent sample set derived from UK Bio-
bank (UKBB) [22]. Questionnaire and biomarker data from participants’ baseline visit (2006–
2010) were used. Each individual with MS at the time of UK Biobank registration (n = 1978)
was randomly matched to four controls (n = 7912), stratified by age, gender, and ethnicity
(white vs non-white). Data including baseline serum 25(OH)D levels, vitamin D supplementa-
tion (yes/no; no dose information available), oily fish consumption, time spent outdoors and
UV sun protection usage were analysed.
Statistical analysis
Statistical analyses for MS register data were performed using SPSS v26 and R (v.1.2.5001).
Geographical mapping was performed using ArcGIS 10.5. Analysis of UK Biobank data was
carried out using R (version 3.6.1). Relationships between categorical variables were analysed
using the chi-squared test of association; non-normally distributed continuous variables were
analysed using the Mann-Whitney U test and the Kruskal Wallis test was used to compare 3
+ groups. Simple linear regression was used to examine the relationship between demographic,
solar and lifestyle behaviour that may affect dose of vitamin D and serum 25(OH)D levels.
Results
Questionnaire data
1768 participants with MS provided questionnaire data. This group consisted of 1722 individ-
uals recruited via the UK MS Register, 25 postal participants and 21 participants from local
MS clinics who returned packs. This group had a wide geographical distribution across the UK
(S1a Fig). Their demographics were consistent with that expected across an MS population;
75% female and predominantly relapsing remitting MS (RRMS) (Table 1).
Table 1. Participant demographics.
All participantsa Biological sampling groupb
MS (n = 1768) MS (n = 388) Control (n = 305) p-value
female, n (%) 1329 (75) 292 (75) 229 (75) 1
male, n (%) 439 (25) 96 (25) 76 (25)
age, median (IQR) 53 (15) 56 (14) 55 (16) 0.37
BMI, median kg/m2 (IQR) 25; 6 25; 6 26; 6 0.02
current smokers, n (%) 70; 5 16; 5 19; 6 0.56
MS type, n;%
RRMS 976; 55 137; 35
SPMS 459; 26 120; 31
PPMS 203; 12 93; 24
Other 130; 7 38; 10
EDSS
median; IQR (n) 6.0; 4 6.5; 3
low EDSS (<6): n; % 247; 49 41; 38
high EDSS (�6); n; % 259; 51 66; 62
adata was missing for the following; BMI 1374 participants, current smoking status 310 participants, EDSS 1262 participants.
bdata was missing for the following: Age, 5 MS and 7 control; BMI, 271 MS and 7 control; current smoking status 69 MS; EDSS 281 MS.
https://doi.org/10.1371/journal.pone.0241459.t001
PLOS ONE Vitamin D in the UK MS population
PLOS ONE | https://doi.org/10.1371/journal.pone.0241459 December 30, 2020 5 / 13
Biological sampling and matched controls
600 sampling kits were posted out to participants. Of 100 kits sent to network sites, 68 were
distributed to potential participants. Sampling packs were sent out to participants from across
the United Kingdom including the Shetland Islands, Orkney Islands, Outer Hebrides, Isle of
Man and Channel Islands (S1b Fig). 388 sample kits (58%) were completed and returned;
those who did not return kits were slightly younger and more likely to be male (S1 Table). 326/
388 returned kits (84%) included a matched control. 17 MS and 17 control participants had
DBS samples excluded or not received, and 7 controls did not complete a questionnaire (4 of
whom provided a DBS). Thus 388 MS cases (371 with DBS), 309 control DBS, and 305 control
questionnaires were included in the analysis (Fig 1).
The demographics of the group from whom biological samples were obtained reflected
stratified sampling across MS type and disability levels (Table 1), with approximately 35%
RRMS, 31% SPMS, 24% PPMS. EDSS scores were available for 107 participants in this group;
the median EDSS was 6.5 (IQR 3) (Table 1). Controls appeared well-matched (Table 1), with
no significant difference in sex or age distribution. Controls had a slightly higher BMI than
participants with MS (median BMI 25 in MS vs 26 in controls; p = 0.02), and there was no dif-
ference in the proportion of current smokers in the two groups.
Vitamin D supplementation between MS and controls
72% (276/386) of the MS participants from the biological sampling group reported taking vita-
min D supplements compared to 26% (79/305) of controls (p<0.001; Table 2). This did not
Table 2. Vitamin D supplementation behaviour and serum 25-(OH)D levels in the biological sampling group.
Supplementing behaviour Serum 25(OH)D levels, median nmol/L (IQR); nc
Taking supplement na (%) p-value Dose IU/day (IQR);nb p-value No supplement p-value Yes supplement p-value
Disease Status
MS (n = 388) 276 (72) <0.001 1600 (3200);238 <0.001 38 (35); 92 0.06 82 (47); 229 <0.001
Control (n = 305) 79 (26) 600 (800);63 44 (21); 194 68 (34); 67
MS split by sex
female 209 (72) 0.67 2000 (3084);181 0.52 38 (36); 70 0.51 82 (46); 168 0.65
male 67 (70) 1000 (4200);57 38 (33); 22 82 (49); 61
MS type
RRMS 99 (73) 0.91 2000 (4000);86 0.11 46 (28); 31 0.10 81 (48); 83 0.11
SPMS 88 (73) 1000 (3200);74 32 (27); 26 79 (48); 69
PPMS 66 (71) 1428 (4000);59 40 (42); 21 88 (51); 58
MS Disability
low EDSS (<6) 29 (71) 0.78 2000 (4100);25 0.08 47 (32); 11 0.13 82 (68); 24 0.76
high EDSS (�6) 45 (68) 1000 (3343);36 28 (44); 16 82 (63); 38
MSISd
physical -Low impact 58 (74) 0.70 2857 (4000);51 0.04 46 (64); 16 0.69 88 (51); 46 0.36
physical–High impact 57 (77) 1000 (3593);44 38 (50); 16 80 (51); 46
psychological -Low impact 61 (75) 0.58 1800 (3750);57 0.77 46 (48); 17 0.76 83 (45); 51 0.66
psychological-High impact 55 (71) 1800 (4200);46 40 (41); 17 84 (48); 43
adata was missing for the following: MS 2 participants, female MS 2 participants, MS type 2 participants, EDSS 281 participants, MSIS 236 participants;
bof the total n that provided supplementation data this n had a dose available;
cof the total n that provided supplementation data this n had serum 25(OH)D levels available;
dMSIS-29 scores were divided into quartiles and comparisons were made between lowest quartile (low impact) and highest quartile (high impact).
https://doi.org/10.1371/journal.pone.0241459.t002
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appear to be restricted to the UK MS Register population: 63% (12/19) MS participants
recruited through clinics supplemented compared to just 10% (2/21) of their matched controls.
There was no difference in reported rates of vitamin D supplementation across gender, MS
type, disability level or score on MSIS (Table 2). Where dose data were available, MS partici-
pants (n = 238) reported a higher median vitamin D supplement dose than controls (n = 63)
(1600 vs. 600 IU/day; p<0.001) (Fig 2a).
Vitamin D supplementation in MS
Exploratory analysis of all MS questionnaire data (nMS = 1768) demonstrated that both partic-
ipants with RRMS and PPMS reported taking a higher vitamin D supplement dose than partic-
ipants with SPMS (median dose 2000 IU/day for both RRMS and PPMS vs 1600 IU/day for
SPMS; p = 0.007) (S2 Table). Linear regression demonstrated that vitamin D supplement dose
decreased with increasing years since diagnosis, although age did not appreciably affect dose
(S3 Table).
Fig 2. Vitamin D supplementation dose and serum 25(OH)D levels in MS and control participants. (a) Distribution of dose (IU/
day) of vitamin D amongst those MS (n = 238) and control (n = 63) that take supplements. (b) Serum 25(OH)D levels (nmol/L) of
MS (n = 321) and control (n = 261) participants. (c) Serum 25-(OH)D levels of MS and control split by Vitamin D supplementation
status.
https://doi.org/10.1371/journal.pone.0241459.g002
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Lifestyle factors influencing serum vitamin D levels
More MS participants identified as either vegetarian or vegan (11% vs 4% controls), p = 0.003.
There was no difference in oily fish consumption (S4 Table). MS participants were more likely
to report rarely spending time on outdoor activities (44% vs 14% controls), p<0.001 (S4
Table), which was strongly associated with disability levels. 71% (47/66) of participants with
high EDSS (�6) rarely participated in outdoor activities compared to 17% (7/41) of partici-
pants with low EDSS (<6) (p<0.001). MS participants were less likely than controls to wear
sunblock (31 vs 13% “never” wear sunblock, p<0.001) (S4 Table). Females, both cases and
controls, were more likely to wear cosmetic sunblock than males (24% females vs 2% males
reported wearing it weekly or more, p<0.001) (S4 Table). There was no significant difference
between MS and control females with respect to cosmetic sunblock usage, p = 0.09 (S4 Table).
Serum 25(OH)D levels
Median serum 25(OH)D levels were higher in MS participants than controls: 71 vs 49nmol/L,
p<0.001 (Fig 2b). MS participants were more likely to have adequate serum levels (defined as
>50nmol/L) (75% MS vs 47% controls) (Table 3). There were no differences in serum vitamin
D levels by gender, MS type or disability level. Subgroup analyses stratified by supplementing
status demonstrated that MS participants who did not supplement (n = 92) had lower median
serum 25(OH)D levels compared to non-supplementing controls (n = 194) (38 vs 44nmol/L,
p = 0.06). Conversely, supplementing MS participants had higher 25(OH)D levels than supple-
menting controls (82 vs 68nmol/L, p<0.001) (Table 2; Fig 2c).
Solar contribution to serum 25(OH)D levels was studied using a linear regression model,
which confirmed the assumption that, in the entire non-supplementing population (i.e. MS
and control), latitude and time spent outdoors were significant contributors to serum 25(OH)
D level (R2 = 0.22, p<0.001). There was a negative association between latitude and serum 25
(OH)D and positive association with time spent outdoors. Season of sampling and use of sun-
block did not affect serum levels (S5 Table).
In the non-supplementing MS population increasing age had a negative association with
serum 25(OH)D in a multivariable model. BMI was not associated with serum 25(OH)D lev-
els. In the supplementing MS population there was a positive association between increasing
vitamin D dose and serum 25(OH)D levels, but age, BMI or solar contributions were not asso-
ciated with serum levels (S5 Table).
Vitamin D levels in UK Biobank
People with MS in UKBB had lower median serum 25(OH)D levels than matched controls (44
vs 47 nmol/L, p<0.001). There was no difference between supplementing participants with
MS vs supplementing controls (median serum 25(OH)D level 57 vs 58nmol/L). Non-supple-
menting people with MS had lower median serum 25(OH)D levels than either group (42nmol/
L) (S6 Table). A lower proportion of people with MS took vitamin D supplementation at
Table 3. Vitamin D status of MS and matched controls based on 25(OH)D levels.
Serum 25(OH)D nmol/L Interpretation MS (n = 322) n (%) Control (n = 264) n (%) p-value
<15 Severe deficiency 4 (1) 2 (1) p<0.001
15–30 Deficiency 29 (9) 30 (11)
30.1–50 Insufficiency 48 (15) 108 (41)
>50 Adequate 241 (75) 124 (47)
https://doi.org/10.1371/journal.pone.0241459.t003
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UKBB enrolment than in our current study, however they were still more likely to do so than
the matched controls (14% vs 6%, p<0.001) (S6 Table).
Discussion
In this case-control study we found a striking difference in vitamin D supplementation
between people with MS and controls. 72% participants with MS report taking vitamin D sup-
plements compared to just 26% of controls. Not only were MS participants more likely to take
vitamin D supplements, but they also took them at higher doses, such that people with MS in
the UK now have overall higher serum 25(OH)D levels than controls. When stratified by sup-
plementation habits we found that non-supplementing people with MS had lower levels of
serum 25(OH)D. These findings carry implications for any future vitamin D supplementation
trial—double blind, placebo-controlled supplementation trials need to take current beha-
vioural patterns into account, and a “treat to target” trial utilising remote sampling is likely the
most feasible study design for any large-scale study.
This study is novel in its use of remote sampling technology. Given the current COVID-19
pandemic, the use of remote technologies to enable clinical trials to continue is highly relevant;
we demonstrate that this is feasible in MS. The wide coverage we were able to achieve using
remote sampling is particularly important when studying an environmentally sensitive end-
point such as serum 25(OH)D. The recruitment of a large pool of participants allowed us to
stratify and select participants for biological sampling which represented all stages of MS with
a range of disability. The use of straightforward sampling techniques carried out by partici-
pants at home allowed us to enrol all members of the MS community regardless of care centre,
location or disability level.
The fact that 1722 people from a total UK MS Register population of 14,991 responded to
the initial invitation to participate is worthy of note. This attrition rate is not entirely unex-
pected. Whilst the UK MS Register has a high number of registrants, only a proportion of
these individuals return to complete surveys–around 4,000 in previous studies [22]. The rela-
tively low rate of responses to the initial questionnaire likely reflects that this was the first UK
MS Register-hosted study where participants were asked to de-anonymise themselves for
research purposes, and where biological sampling was required. The rate of return of usable
sample packs (58%) is in keeping with other studies requiring sample return.
This study is not without limitations. As recruitment primarily took place through a volun-
tary MS Register, it could be argued that this high rate of supplementation resulted from a par-
ticipation/recruitment bias with an a priori interested population. This could have led to the
recruitment of a population who were far more likely to be supplementing than the general
MS population, limiting the generalisability of these results. A recent clinical trial of vitamin D
supplementation in MS reported that around 17% participants were taking vitamin D supple-
ments at baseline [9], which is closer to the proportion of supplementing participants seen in
UK Biobank. However, this trial could conceivably have been enriched for patients not taking
supplements due to recruitment bias. Furthermore, it could be argued that the participants in
our study represent a subset of patients particularly interested in diet and lifestyle factors, and
that lifestyle-aware people with MS may also be likely to have lifestyle-aware friends.
People were aware from the information sheet that the purpose of the study was to establish
vitamin D levels across the UK MS population. However, no overt reference was made to either
an underlying hypothesis linking vitamin D deficiency to MS or recommended intakes. The
population taking part in the UK MS Register represent a more engaged and educated group
with respect to vitamin D supplementation and MS. However, the recruitment of a subset of
individuals directly from MS clinics across the UK enabled us to estimate bias related to
PLOS ONE Vitamin D in the UK MS population
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method of recruitment. Similarly high rates of supplementation were found in MS participants
recruited via both means. It seems possible that these biases would also impact on recruitment
to any potential vitamin D trials, and must be taken into account in any trial design.
We were unable to include measures of disease activity, such as relapse and/or MRI data in
this study. EDSS data were only available on a proportion of participants. Whilst asking indi-
viduals about retrospective relapse data would have been possible, the potential for recall bias
along with the influence of relapses on behaviour would have significantly limited the interpre-
tation of data collected in this way. The finding that supplementation rates decreased with
increasing years since MS diagnosis is interesting; potential reasons for this could include
either individuals stopping supplementation as their MS progresses, or alternatively it could
reflect changing advice from neurologists. This finding may be worthy of additional studies
examining the drivers of both starting and of stopping supplementation.
Participant recruitment of age and sex-matched controls may have induced bias related to
overmatching, however the exclusion of household controls mitigates this to some degree.
Whilst similarities may remain around socioeconomic status and other lifestyle factors, we
see that the impact of differential vitamin D status far outweighs this.
Whilst the UKBB population demonstrated a lower rate of vitamin D supplementation
amongst people with MS compared to our current study, vitamin D supplementation was still
significantly higher than in controls. The reason(s) for the discrepancy between vitamin D
usage between the current study and the UK Biobank population is unclear, but at least some
of this difference may be attributed to the changes in vitamin D usage over the last 10 years.
UKBB baseline data was collected 10–14 years ago, and attitudes towards vitamin D supple-
mentation in the UK have changed significantly over this time [23]. Our clinical experience
reflects this finding that overall supplementation has increased over the past 10–15 years, and
advice regarding vitamin D has now become mainstream, particularly in MS clinics. The rea-
sons for the difference between supplementation in the UK MS Register and in UK Biobank is
therefore likely multifactorial.
Due to the cross-sectional nature of this observational case-control study we are unable to
make inferences with regard to vitamin D status and disease progression. However, the poten-
tial to re-recruit via the same online platform for follow-up remains. The use of self-reported
behaviours is a further limitation, however, the dose-response to vitamin D supplementation
and validation using photographs of supplements overcome this to some degree. The UK MS
Register population is predominantly White British [17] and this study needs to be replicated
in an ethnically diverse population. Finally, whilst the return rate of biological samples was
high for a survey-based study, it remains significantly lower than in direct sampling studies,
and this must be considered in future remote sampling studies.
In conclusion we have characterised the behaviours influencing vitamin D and carried out
a detailed analysis of the vitamin D status across the UK MS population. People with MS are
more likely to supplement with vitamin D and at higher doses than matched controls. After
supplementation behaviours, outdoor activity had the most significant impact on serum 25
(OH)D levels. The solar contribution to vitamin D levels was evidenced through both positive
association with time spent outdoors and a negative association with increasing latitude. This
study underlines the importance of considering participant lifestyle, behavioural and baseline
vitamin D status when considering the design of interventional trials using vitamin D in MS.
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S1 Fig. Distribution of study participants across the UK. (a) The distribution of the 1768
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